Aneuploidy—an abnormal number of chromosomes—is a defining characteristic of many human malignancies that contributes to therapeutic resistance and aggressive tumor behavior. The reviewed evidence indicates that pharmacologic antagonism of CDK2 activates a death program called anaphase catastrophe, which selectively kills aneuploid cancer cells by triggering mitotic failure and apoptosis.
An important clinical advantage described is the relative specificity of this mechanism: CDK2 inhibition provokes apoptotic death in aneuploid tumor cells while largely sparing non-aneuploid epithelial cells. This selective toxicity suggests a favorable therapeutic window in which aneuploid cancers can be targeted without equivalent damage to normal epithelial tissues.
Despite robust elimination of many aneuploid cancer cells through CDK2-induced anaphase catastrophe, the review highlights a persistent, residual population of polyploid cancer cells that survives treatment. These polyploid cells are observed across both in vitro and in vivo experimental settings and are resistant to the apoptotic effects that eliminate other aneuploid cells following CDK2 inhibition.
The existence of this apoptosis-resistant polyploid fraction provides a biologically plausible mechanism for clinical drug resistance: even when the majority of aneuploid cells succumb to anaphase catastrophe, the surviving polyploid subset can maintain tumor persistence and potentially drive relapse.
To characterize the resistant polyploid population, investigators isolated these cells and examined their expressed proteins. The review reports that the apoptosis-resistant polyploid cells are enriched for expression of CDK1 and for multiple kinesin superfamily proteins (KIFs).
This molecular profile implicates alternative mitotic regulators and microtubule motor proteins in the survival of polyploid cells after CDK2 antagonism. The enrichment of CDK1 suggests that CDK1-dependent cell-cycle or checkpoint functions may compensate when CDK2 is inhibited. Elevated KIF expression points to altered mitotic spindle dynamics or intracellular transport mechanisms supporting polyploid cell viability.
Given the resistance phenotype associated with polyploid survivors, the review describes preclinical strategies that combine CDK2 inhibition with antagonists directed at CDK1 or specific KIF family members. In experimental models, this combined approach markedly augmented anticancer effects compared with CDK2 inhibition alone.
The combination rationale is mechanistic: eliminating the compensatory programs (for example, CDK1 activity or KIF-dependent processes) reduces the capacity of polyploid cells to survive after CDK2-triggered anaphase catastrophe, thereby promoting broader tumor cell eradication. The review frames this combined regimen as clinically tractable and translationally promising based on the reported preclinical outcomes.
The central translational message is that while CDK2 antagonism selectively targets and kills many aneuploid cancer cells via anaphase catastrophe, the emergence of an apoptosis-resistant polyploid population limits single-agent efficacy. Therefore, the authors advocate testing combined regimens—pairing CDK2 inhibitors with CDK1 or KIF antagonists—in future clinical trials to determine whether such combinations can overcome residual resistance and achieve more complete tumor eradication.
The review positions these combination strategies as feasible next steps and recommends that clinical studies explore whether the synergistic effects seen preclinically translate into improved patient outcomes in aneuploid malignancies.
The abstract-based summary provided in this source does not report several details that would be important for clinical translation, including specific inhibitor names, dosing schedules, the exact experimental systems used, quantitative efficacy or toxicity data, or prospective clinical trial designs. These methodological and outcome specifics are not included in the abstract and would require consultation of the full article for complete evaluation.
In addition, the review notes biological complexity: the presence and behavior of polyploid survivors in diverse tumor types, and the potential for additional compensatory resistance mechanisms, mean that clinical outcomes may differ from preclinical predictions. The recommendations therefore emphasize testing combined regimens in trials, with attention to defining biomarkers, safety, and durability of response.
Overall, the review synthesizes available preclinical findings to argue that CDK2 inhibition can selectively trigger anaphase catastrophe in aneuploid cancers but that durable eradication likely requires combination strategies that also target CDK1 or KIF-dependent survival pathways.